Mito Biopharma has relied during its formative years largely on the established expertise and know-how of its founder, Dr. Jin (see bio). Dr. Jin has initially conducted extensive studies with a prototype drug, Niclosamide (see publications) to establish a strong preclinical proof of concept demonstrating the relevance and viability of defining a drug discovery program for IND-viable compounds. As the testing of mitochondrial uncouplers is mechanism specialized, Dr. Jin’s lab has established relevant in vitro screening tests and also key in vivo animal models to allow for rapid testing of potential lead compounds. More importantly, proprietary know-how allows rational design of mitochondrial uncouplers with desired PD, PK and ADME properties for different indications. Mito Biopharma has signed a R&D collaboration with Rutgers University to implement a drug discovery program utilizing existing synthetic chemistry expertise in synergy with technical capabilities established in the Jin lab. More recently, Mito Biopharma has enhanced its discovery program with outside CRO expertise to allow rapid synergy to transition to lead compound characterization. Mito Biopharma anticipates initiation of IND-enabling studies in 2019.